Screening of epigenetic modifiers identifies novel host-directed agents that suppress HIV-1 replication in primary human macrophages
- 1Cornell University
Abstract
Epigenetic modifications play a critical role in diverse biological processes, including HIV-1 replication in lymphoid and myeloid cells, particularly in the establishment and maintenance of latency. As such, epigenetic targets represent potential candidates for novel host directed therapy (HDT). In this study, we developed a novel in vitro screening platform using human primary macrophages, including both monocyte-derived macrophages and alveolar macrophages, infected with a replication-competent luminescent virus. In contrast to previous screens, this platform enables the identification of compounds and epigenetic targets that modulate viral replication during a spreading infection, capturing not only transcriptional regulation but other vulnerabilities across the complete HIV-1 life cycle. Our data reveal multiple novel compounds targeting distinct epigenetic regulators, effectively inhibiting viral replication at various stages in primary macrophages, which may serve as potential candidates/targets for HDT.
Related
- Image-based transposon screening reveals a flavin reductase that restrains intracellular Salmonella replication in macrophages
- Comparative screening identifies gga-miR-204 as a nutrient-responsive miRNA that targets MAP1LC3B and promotes infectious bursal disease virus replication in HD11 cells
- Sulforaphane targets Leishmania promastigotes to inhibit parasite motility and alters host autophagy to suppress parasite replication in macrophages
- Epigenetic regulation of DPP4 receptor expression by NONO enables replication of MERS-CoV
- High-throughput platforms for genetic perturbation screening using CRISPR/Cas9 in human iPSC-derived macrophages for drug discovery
BibTeX
@misc{bury2026screening,
title = {{Screening of epigenetic modifiers identifies novel host-directed agents that suppress HIV-1 replication in primary human macrophages}},
author = {G. Le Bury and C. Mandalasi and J. Rhen and D. Gludish and S. Boliar and H. Mwandumba and D. G. Russell},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.01.748500},
url = {https://www.biorxiv.org/content/10.64898/2026.09.01.748500v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - Screening of epigenetic modifiers identifies novel host-directed agents that suppress HIV-1 replication in primary human macrophages
AU - G. Le Bury
AU - C. Mandalasi
AU - J. Rhen
AU - D. Gludish
AU - S. Boliar
AU - H. Mwandumba
AU - D. G. Russell
PY - 2026
DA - 2026/09/01
PB - bioRxiv
DO - 10.64898/2026.09.01.748500
UR - https://www.biorxiv.org/content/10.64898/2026.09.01.748500v1
AB - Epigenetic modifications play a critical role in diverse biological processes, including HIV-1 replication in lymphoid and myeloid cells, particularly in the establishment and maintenance of latency. As such, epigenetic targets represent potential candidates for novel host directed therapy (HDT). In this study, we developed a novel in vitro screening platform using human primary macrophages, including both monocyte-derived macrophages and alveolar macrophages, infected with a replication-competent luminescent virus. In contrast to previous screens, this platform enables the identification of compounds and epigenetic targets that modulate viral replication during a spreading infection, capturing not only transcriptional regulation but other vulnerabilities across the complete HIV-1 life cycle. Our data reveal multiple novel compounds targeting distinct epigenetic regulators, effectively inhibiting viral replication at various stages in primary macrophages, which may serve as potential candidates/targets for HDT.
ER -